#BioLineRx
BioLineRx enters into $5.6mm royalty monetization transaction w/ Soleus Capital
*Sale of future Aphexda royalties
#$BLRX retains rights to future commercial milestone payments
*Proceeds will support GLIX1 development & partial loan repayment to Blackrock
*30Nov close
finance.yahoo.com/healthcare/a...
BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into an agree...
finance.yahoo.com
November 18, 2026 at 1:10 PM
BioLineRx Secures $5.6 Million Funding through Royalty Monetization Deal#Israel#Tel_Aviv#BioLineRx#APHEXDA#Soleus_Capital
BioLineRx Secures $5.6 Million Funding through Royalty Monetization Deal
BioLineRx Ltd. has finalized a $5.6 million royalty monetization agreement with Soleus Capital to augment its funding for oncological research and drug development.
third-news.com
November 18, 2026 at 12:16 PM
BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
BioLineRx (BLRX) signed an agreement with Soleus Capital Management and its affiliates to sell future APHEXDA royalties for a one-time $5.6 million payment. Soleus will acquire BioLineRx’s 14.4% royalty interest in future APHEXDA net sales under its license with Ayrmid Pharma. BioLineRx retains rights to potential commercial milestone payments and royalties attributable to periods before closing. The deal is expected to close on or about November 30, 2026.BioLineRx plans to use the non-dilutive proceeds to support research and development, including GLIX1, and to make a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with that repayment, BioLineRx’s current $4 million minimum cash balance requirement will be eliminated. The GLIX1 Phase 1/2a trial is enrolling the fourth of five planned dosing cohorts.
www.stocktitan.net
November 18, 2026 at 12:00 PM
BioLineRx and Hemispherian Unveil Promising Results for GLIX1 at SNO 2026#BioLineRx#GLIX1#Hemispherian
BioLineRx and Hemispherian Unveil Promising Results for GLIX1 at SNO 2026
At the Society for Neuro-Oncology 2026 meeting, BioLineRx and Hemispherian shared significant updates on GLIX1, focusing on its effectiveness in treating glioblastoma.
third-news.com
November 16, 2026 at 12:25 PM
BioLineRx & Hemispherian presented GLIX1 in 2 posters @ SNO
*Brain PK/PD data
*Review preclinical data & describe Ph1/2 design
*Review antitumor activity of GLIX1
*Held 12-15Dec
#$BLRX
finance.yahoo.com/healthcare/a...
BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology co...
finance.yahoo.com
November 17, 2026 at 12:49 PM
BioLineRx (#$BLRX) and Hemispherian presented data at ESMO: GLIX1 boosted PARP inhibitor activity in HR-proficient ovarian cancer models. Preclinical only.

prismmarketview.com/biolinerx-an...
BioLineRx and Hemispherian Report Encouraging GLIX1 Combination Results in Ovarian Cancer Models
Key Points GLIX1 enhanced the activity of three PARP inhibitors in laboratory studies of HR-proficient ovarian cancer cells. In a mouse model using pati
prismmarketview.com
October 23, 2026 at 3:56 PM
Breakthrough Research on GLIX1 Enhances Efficacy of PARP Inhibitors in Ovarian Cancer Treatment#Israel#Tel_Aviv#PARP_inhibitors#GLIX1#Hemispherian
Breakthrough Research on GLIX1 Enhances Efficacy of PARP Inhibitors in Ovarian Cancer Treatment
Recent findings presented by BioLineRx and Hemispherian showcase the potential of GLIX1 to enhance PARP inhibitor efficacy in HR-proficient ovarian cancer, promising new hope for treatment.
third-news.com
October 23, 2026 at 11:13 AM
BioLineRx and Hemispherian to Present GLIX1 Data at SNO Meeting

BioLineRx and Hemispherian are set to present preclinical and Phase 1/2a trial design data for their first-in-class cance…

Read more: https://embers.news/article/biolinerx-and-hemispherian-to-present-glix1-data-at-sno-meeting-442423
BioLineRx and Hemispherian to Present GLIX1 Data at SNO Meeting
BioLineRx and Hemispherian are set to present preclinical and Phase 1/2a trial design data for their first-in-class cancer therapy candidate, GLIX1, at the upcoming 31st Society for Neuro-Oncology Annual Meeting & Education Day. The presentations arrive as the clinical-stage biotech collaboration ad
embers.news
October 14, 2026 at 10:31 AM
BioLineRx (#$BLRX) and Hemispherian will present two GLIX1 posters at SNO 2026 on Nov. 13: preclinical glioblastoma research and the Phase 1/2a trial design. No human efficacy results disclosed.

prismmarketview.com/biolinerx-an...
BioLineRx and Hemispherian Bring GLIX1 Brain Cancer Research to SNO 2026
Key Points BioLineRx and Hemispherian will present two GLIX1 posters at the Society for Neuro-Oncology annual meeting in Philadelphia. Both presentation
prismmarketview.com
October 8, 2026 at 3:54 PM
BioLineRx and Hemispherian Showcase GLIX1 Research at Annual Neuro-Oncology Conference#Israel#Tel_Aviv#BioLineRx#GLIX1#Hemispherian
BioLineRx and Hemispherian Showcase GLIX1 Research at Annual Neuro-Oncology Conference
The collaboration between BioLineRx and Hemispherian highlights promising GLIX1 research aimed at treating glioblastoma at the upcoming Society for Neuro-Oncology meeting.
third-news.com
October 8, 2026 at 11:36 AM
BioLineRx to present GLIX1 data @ EANO '26
*2 abstracts accepted
*Addresses preclinical efficacy in orthotopic GBM models
*24-27Sep in Rome
#$BLRX
finance.yahoo.com/healthcare/a...
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology co...
finance.yahoo.com
September 11, 2026 at 12:36 PM
Exciting Developments from BioLineRx and Hemispherian at EANO 2026 Conference#Israel#Tel_Aviv#BioLineRx#GLIX1#Hemispherian
Exciting Developments from BioLineRx and Hemispherian at EANO 2026 Conference
BioLineRx and Hemispherian are set to present promising preclinical results for their cancer treatment GLIX1 at the EANO 2026 conference in Rome.
third-news.com
September 10, 2026 at 11:08 AM
September 1, 2026 at 4:42 PM
$BLRX — Foreign Issuer Report

BioLineRx Ltd. entered into a securities purchase agreement on August 27, 2026, for a registered direct offering and concurrent private placement, raising approximately $3.75 million in gross proceeds.

🧵 continued ↓
August 31, 2026 at 9:46 PM
BioLineRx Shares Promising Updates and Financial Insights for Q2 2026#Israel#Tel_Aviv#oncology#BioLineRx#GLIX1
BioLineRx Shares Promising Updates and Financial Insights for Q2 2026
BioLineRx has updated investors on its Q2 2026 performance and ongoing clinical trials, emphasizing progress in anti-cancer therapy GLIX1.
third-news.com
August 31, 2026 at 11:14 AM
BioLineRx reports 2Q
*Call @ 8:30 am ET
*GLIX1 in GBM Ph1/2a ongoing
*Aphexda royalty revenue of $0.3mm
#$BLRX
ir.biolinerx.com/news-release...
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | BioLineRx
The Investor Relations website contains information about BioLineRx's business for stockholders, potential investors, and financial analysts.
ir.biolinerx.com
August 31, 2026 at 11:57 AM